Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease
US11939577B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 24, 2019 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | May 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antisense RNAs targeting PMP22 and able to inhibit from 40% to 60% the expression of PMP22 in the cells and a pharmaceutical composition comprising thereof. The antisense RNAs are preferably siRNA and are preferably provided in the form of nanoparticles. The present invention also relates to the use of these antisense RNAs targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.